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ABSTRACT
The alkyltransferase-like (ATL) proteins contain
primary sequence motifs resembling those found
in DNA repair O6-alkylguanine-DNA alkyltransferase
proteins. However, in the putative active site of
ATL proteins, a tryptophan (W83) residue replaces
the cysteine at the known active site of alkyltrans-
ferases. The Escherichia coli atl gene was expressed
as a fusion protein and purified. Neither ATL nor
C83 or A83 mutants transferred [3H] from [3H]-methyl-
ated DNA to themselves, and the levels of O6-methyl
guanine (O6-meG) in substrate DNAwere not affected
by ATL. However, ATL inhibited the transfer of
methyl groups to human alkyltransferase (MGMT).
Inhibition was reduced by prolonged incubation
in the presence of MGMT, again suggesting that
O
6-meG in the substrate is not changed by ATL.
Gel-shift assays show that ATL binds to short
single- or double-stranded oligonucleotides contain-
ing O6-meG, but not to oligonucleotides containing
8-oxoguanine, ethenoadenine, 5-hydroxycytosine
or O4-methylthymine. There was no evidence of
demethylation of O6-meG or of glycosylase or endo-
nuclease activity. Overexpression of ATL in E.coli
increased, or did not affect, the toxicity of N-methyl-
N 0-nitro-N-nitrosoguanidine in an alklyltransferase-
proficient and -deficient strain, respectively. These
results suggest that ATL may act as a damage
sensor that flags O6-meG and possibly other O6-
alkylation lesions for processing by other repair
pathways.
INTRODUCTION
O6-methylguanine (O6-meG) is a potentially mutagenic and
toxic lesion in DNA that is one of the many products of
damage by certain classes of carcinogenic and chemothera-
peutic alkylating agents. The processing of this lesion is thus
of considerable interest in both the etiology and treatment of
cancer (1,2). It is well established that the biological effects of
such agents can be extensively prevented by the highly con-
served DNA repair protein O6-alkylguanine-DNA alkyltrans-
ferase, which reverses O6-meG damage in DNA by the
stoichiometric and auto-inactivating transfer of the methyl
group to a cysteine residue in its active site (PCHRV)
(3–5). Some prokaryotes, including Escherichia coli, contain
two alkyltransferase genes: the inducible ada (6,7) and the
constitutively expressed ogt (8), and other prokaryotes
contain only one of these genes. Human cells express a
single O6-alkylguanine-DNA-alkyltransferase [referred to as
MGMT (9)].
In silico analysis has revealed a family of genes we have
called the alkyltransferase-like (ATL) genes because of their
extensive amino acid sequence similarity to the alkyltrans-
ferase proteins (5). The E.coli ATL is 21 and 19% identical
and 34 and 30% similar to OGT and MGMT, respectively.
Alignment of ATL and other alkyltransferase sequences
(Table 1) shows that in ATL, the alkyltransferase active
site cysteine residue (C145) has been replaced with a conserved
tryptophan (W83 in the E.coli ATL). ATL proteins are com-
mon among prokaryotes, with Deinococcus radiodurans R1
being an example of a prokaryotic organism containing ATL
that does not have a recognizable alkyltransferase gene
(i.e. one encoding the characteristic PCHRV). Within the
eukaryotes, Schizosaccharomyces pombe contains a sequence
homolog of ATL. Interestingly, this organism also does
not possess an alkyltransferase protein. The method by
*To whom correspondence should be addressed. Tel: +44 161 446 3183; Fax: +44 161 446 3109; Email: GMargison@picr.man.ac.uk
Ó The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 12 3837–3844
doi:10.1093/nar/gki696
Published online July 13, 2005
 a
t U
n
iv
e
rs
ity
 o
f N
e
w
c
a
s
tle
 o
n
 J
a
n
u
a
ry
 3
1
, 2
0
1
1
n
a
r.o
x
fo
rd
jo
u
rn
a
ls
.o
rg
D
o
w
n
lo
a
d
e
d
 fro
m
 
which such organisms process O6-meG in DNA, if any, is not
known.
In order to define the possible role of ATL in the processing
of alkylation damage in DNA, we isolated and over-
expressed the gene from E.coli and purified the protein. We
characterized the protein, and two site-directed mutants in a
series of in vitro assays using, as putative substrates, N-[3H]-
methyl-N-nitrosourea-methylated DNA and short synthetic
oligonucleotides containing O6-meG or other modified
bases. We also assessed the effect of ATL overexpression
in E.coli.
MATERIALS AND METHODS
Materials
All oligonucleotides containing DNA lesions were purchased
from DNA technology A/S. PCR primers were synthesized by
MWG. E.coli XL-1-blue bacterial strain was purchased
from Novagen. Vent polymerase, restriction enzymes,
factor Xa and amylose-resin were purchased from New Eng-
land Biolabs. Ampicillin, isopropyl b-D-thiogalactopyranoside
(IPTG), calf thymus DNA, VIVAspin (10 000 Da molecular
weight cut-off) spin columns and most other biochemical
reagents were purchased from Sigma. T4 polynucleotide
kinase was purchased from Roche Applied Science. Molecular
biology kits were purchased from Qiagen.
Generation of pMAL-2c constructs for the expression of
maltose-binding protein (MBP) fusion proteins
Based on the predicted DNA sequence of an O6-meG-DNA
methyltransferase-like protein (GenBank accession no.
AE000151), specific primers were synthesized and used for
the amplification of ATL from E.coli genomic DNA. The
primers used contained restriction enzyme sites for EcoRI
(sense) and BamHI (antisense), which are indicated in
boldface as follows: (i) 50-CGGAATTCATGCGTATGGAC-
GAATTTTATACAAAG-30 (sense) and (ii) 50-CGGGATCC-
TTAAGGCTTCCACATGTATTCTGG-30 (antisense) (ATG
start codon underlined). PCR amplifications were carried out
using Vent polymerase with 50 ng of E.coli genomic DNA as a
template (genomic DNA was purified from AB1157 E.coli
using a Qiagen genomic DNA purification kit) under the
following conditions: initial denaturation for 1 min at 95C
followed by 25 cycles of denaturation (at 95C for 45 s),
annealing (at 55C for 45 s) and extension (at 72C for
1 min). The PCR product (409 bp) was digested with
EcoRI and BamHI restriction enzymes and the band purified
by electrophoresis on 1% agarose gel. The DNA was isolated
from the gel using a Qiagen gel extraction kit and ligated into
the pMAL-2c vector digested with the same enzymes to form
pMAL-2c-ATL. The coding region of the construct was
sequenced to ensure that no mutations were introduced during
the production. The cDNA for human MGMT (GenBank
accession no. M29971) was PCR amplified as above using
the following primers: 50-CGGAATTCATGGACAAG-
GATTGTGAAATGAAACG-30 (sense) and 50-CGGGACC-
TCAGTTTCGGCCAGCAGGCGG-30 (antisense) (ATG start
codon underlined). The pMAL-2c-hMGMT construct was
then generated and the sequence fidelity verified using the
protocols described above.
Generation of C83 and A83 ATL mutants
To generate the C83 and W83 ATL mutant genes, site-directed
mutagenesis was performed using a two-step PCR strategy.
For the C83 ATL mutant, primers (i) (ATL 50 primer described
above) and (iii) 50-GGCAGCACCTTACCCGTGCCACCG-
GGTGGTTAATCG-30 (antisense) (underlined bases indicate
W83 to C83 codon substitution) were used to generate a 50 ATL
fragment (265 bp) encoding the base change. The primers (ii)
(30 ATL primer described above) and (iv) 50-CGATTAAC-
CACCCGGTGGCAGGGTAAGGTGCTGCC-30 (sense) were
then used to generate the 30 fragment (129 bp) encoding the
base change. Both PCR products were purified by electrophor-
esis on a 1% agaorse gel and the DNA isolated using a Qiagen
gel extraction kit. Equal amounts (25 ng) of the 50 and 30
overlapping PCR fragments were then mixed and PCR amp-
lified with primers (i) and (ii) to generate the full-length C83
ATL cDNA. To generate the A83 variant, primers (iii) and (iv)
were substituted for primers (v) 50-GGCAGCACCTTACC-
CGCGGCACCGGGTGGTTAATCG-30; and primers (vi) and
Table 1. Amino acid sequence alignments of the homologous regions of some alkyltransferase and ATL proteins
Human MGMT (P_002403) 113 SYQQLAALAGNPKAARAVGGAMRGNPVPIL--IPCHRVVCSSGAVGNYSGG--LAVKEWLLAHEG
S.cerevisiae MGMT (AAA34780) 137 TYGDIAKRIGKPTAARSVGRACGSNNLALL--VPCHRIVGSNRKLTGYKWS--CKLKEQLLNNEK
E.coli Ogt (CAA68548) 107 HYGQLAEQLGRPGAARAVGAANGSNPISIV--VPCHRVIGRNGTMTGYAGG--VQRKEWLLRHEG
E.coli Ada (AAA23412) 289 SYQQLANAIGKPKAVRAVASACAANKLAII--IPCHRVVRGDGTLSGYRWG--VSRKAQLLRREA
M.tuberculosis ATL (AAK47642) 26 TYGDIAALAGLS-SPRIVGWIMRTD--SSD--LPWHRVIRASGRPAQHLAT----RQLELLRAEG
Pseudomonas ATL (AAL19421) 51 SYGQLAELAGLGRAARWVGRTLSQLPVDTR--LPWHRVLGAGGRISLPADSPGGREQRARLREEG
E.coli ATL (AAC73557) 51 TYGDVAKLAGSPRAARQVGGVLKRLPEGST--LPWHRVVNRHGTISLTGPDL--QRQRQALLAEG
S.typhimurium ATL (AAL19421) 51 TYGDVARLAGSPRAARQVGGVLKRLPEGST--LPWHRVVNRHGAISLTGPDL--QRQRQALLAEG
Y.pestis ATL (CAC92374) 102 TYGDIAQLIGSPRAARQVGGVLKRLPEGSA—-LPWHRVINRYGEISLTGDDY--LRQKKALVAEG
V.cholerae ATL (AAF94224) 22 TYGAIAKMAGYPGYARHVGKALGHLPEGSQ--LPWFRVINSQGKISLQGEDF--VRQRQLLLAEG
Deinococcus ATL (AAF10005) 49 TYGQLALLAGQPGAARQAGAVMHSLKD-SD--LPWQRVINAQGRVSTYKVGLG-EVQEGLLRAEG
S.pombe ATL (CAB54827) 24 TYGEIARYVGMPSYARQVGQAMKHLHPETH--VPWHRVINSRGTISKRDISAGEQRQKDRLEEEG
S.coelicolor ATL (CAC01312) 87 TYGDVAEYLEEG-GPRQVGRVMSLY--GGG--VPWWRVVRADGVLLAGHEL----EALDRYREEG
Lactococcus ATL (AAK05902) 25 SYRDVGALAGLPNGARQVSRILHSMSKKYE--LPWWRVVRSDRTIGLPEPAKS--EQMELLKKEG
Myxococcus ATL (AAB60209) 58 SYAQVALYAGRPGAARGVGREMATLPQQPELPLPWWRVTRSDGTL-APQVAQ---EQARRLRAEG
The highly conserved residues are highlighted. Accession numbers are given in parentheses. Numbers indicate residue numbers.
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(iv) 50-CGATTAACCACCCGGTGCCGGGGTAAGGTGC-
TGCC-30 (underlined bases indicate W83 to A83 codon sub-
stitution). pMAL-2c constructs were generated as described
above.
Expression and purification of recombinant
MBP fusion proteins
To express and purify the MBP fusion proteins, the pMAL-2c
constructs were transformed into competent XL-1 blue E.coli.
Fusion proteins expressed from this plasmid contain an MBP
tag at the N-terminus and can be purified using the affinity of
MBP for amylose resin. To express the protein, a single colony
was grown in Luria–Bertani broth (LB) (500 ml with 50 mg/ml
ampicillin; Sigma) to an OD600 of 0.6. Protein expression was
induced by the addition 0.4 mM IPTG and the cultures were
incubated at 37C for 3 h. The cells were cooled on ice then
harvested by centrifugation at 2500 g Bacterial cell pellets
were resuspended in 20 ml of binding buffer [20 mM Tris–
HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 3 mM DTT, 10%
glycerol and 300 ml protease inhibitor cocktail (Sigma)] and
extracts were prepared by sonication (four 20 s pulses, setting
4.5; Sonicator XL; Heat Systems). The samples were then
centrifuged at 2500 g at 4C for 20 min. The soluble fraction
was applied to 1 ml of amylose resin and incubated at 4C for
2 h. The resin was centrifuged at 1500 g for 30 s then washed in
binding buffer. This process was repeated three times. The
fusion proteins were eluted in 10 ml of binding buffer
supplemented with 10 mM maltose. A VIVAspin 20 ml cen-
trifugal concentrator (10 000 Da molecular weight cut-off)
was used to concentrate the proteins. The final protein
concentration was determined using a standard Bradford
(10) assay.
Factor Xa cleavage of MBP fusion proteins
Factor Xa digest reactions were carried out using 1 mg of
factor Xa, 5 ml of 10· reaction buffer (200 mM Tris–HCl,
pH 8.0, 1 M NaCl and 20 mM CaCl2) and 25 mg of MBP
fusion protein in a total volume of 50 ml. The reactions were
incubated at 23C for 18 h. The efficiency of the digest was
assessed by resolving the cleavage products on a 14% SDS–
polyacrylamide gel.
50 End labelling of oligonucleotides with [g-32P]ATP
Substrate oligonucleotides containing DNA adducts were
synthesized by DNA technologies (Table 2). Labelling reac-
tions were carried out using 5 pM of oligonucleotide, 2 ml of
[g-32P]ATP (6000 Ci/mmol; Amersham Biosciences), 0.5 ml
of PNK (Roche), 2 ml of 10· reaction buffer (500 mM Tris–
HCl, pH 8.2, 100 mM MgCl2, 1 mM EDTA, 50 mM DTT and
1 mM spermidine) in a total volume of 20 ml. Reactions were
incubated at 37C for 60 min, then cooled on ice. The volume
was adjusted to 40 ml with TE (0.1 M Tris–HCl, pH 7.5 and
10 mM EDTA) and passed through a G25-microspin column
(Amersham Biosciences). Labelling efficiency was measured
by counting 1 ml of the labelled oligonucleotide for 1 min in a
scintillation counter. The labelled oligonucleotide (5 pM) was
annealed with the complimentary oligonucleotide (10 pM) in
a volume of 50 ml supplemented with 500 mM NaCl. The
reaction mixture was heated to 80C for 2 min and allowed
to slowly cool to room temperature (2–3 h). To confirm
annealing, an aliquot equivalent to 20 000 c.p.m. was added
to 3 ml of 3· non-denaturing gel loading buffer [30% (v/v)
glycerol, 0.25% (w/v) xylene cyanol and 0.1% (w/v)
bromophenol blue] in a total of volume of 10 ml and analysed
on a 20% non-denaturing polyacrylamide gel.
Gel-shift and cleavage assay analysis
Reaction mixtures (20 ml) contained 2.5 pM of MBP fusion
protein and 5 fmol of 50-32P-labelled oligonucleotide substrate
in buffer I (50 mM Tris–HCl, pH 8.3, 3 mM DTT and 1 mM
EDTA). Incubations were carried out at 37C for 15 min.
Reactions that were subjected to subsequent PstI digestion
step were first purified by phenol/chloroform followed by
ethanol precipitation. Samples were analysed by either
denaturing (20%) or non-denaturing (lower half 20%/
upper half 5%) PAGE using Mini-PROTEAN II apparatus
(Bio-Rad).
Alkyl transfer assays
A standard assay procedure (10) was used to monitor the
transfer of radioactivity from F-methylated DNA calf thymus
DNA to protein and the inhibition of this reaction by ATL.
Purified MBP–ATL, MBP–MGMT fusion proteins or mutants
thereof and extracts of E.coli harbouring the overexpres-
sing vector, pRBShAT (11) were used as indicated. Aliquots
(100 ml) of substrate DNA containing 1000 c.p.m. O6-meG
in buffer I were incubated at 37C for the times indicated with
various volumes of proteins or extract in a total volume to
300 ml made up with buffer I containing BSA (1 mg/ml;
IBSA). In assays containing both ATL and MGMT, the
former was added to the substrate and incubated at 37C
for 10 min before the addition of MGMT. Following
incubation, processing of the samples was as described
previously (10).
High-performance liquid chromatography (HPLC)
analyses
Aliquots of [3H]-methylated substrate DNA (10 ml, 2 mg/ml
containing6000 c.p.m. inO6-meG) were incubated for 6 h at
37C with either 5 ml of the MGMT preparation, 10 ml of
the ATL preparation or both (in which case, ATL was pre-
incubated with substrate for 10 min at 37C before the addition
of MGMT) or IBSA alone (control) in a total volume of 45 ml
IBSA in capped 500 ml tubes. DNA was then hydrolysed to
purine bases by the addition of 5 ml of 1 M HCl and heating at
75C for 30 min. Samples were centrifuged and supernatants
mixed with the marker bases 3-meA, 7-meG and O6-meG.
Samples were applied to a strong cation exchange column
(Waters Spherisorb 5 m SCX, 5 mm · 160 mm) and eluted
Table 2. Sequences of DNA adduct containing oligonucleotides
O6-meG GGACTG6CAGCTCCGTGCTGGCCC
O4-meT GGACT4GCAGCTCCGTGCTGGCCC
8-oxoG GGACTG8CAGCTCCGTGGTGGCCCGAATTC
5-OHC CTGGGAC5TGCAGCTCCGTGGTGGCCCGAATTC
ethenoA GGACTGCAeGCTCCGTGGTGGCGAATTC
The complimentary oligonucleotide sequences are not shown.
Nucleic Acids Research, 2005, Vol. 33, No. 12 3839
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with 0.2 M ammonium phosphate–acetate buffer, pH 2.85 at
1 ml/min. Fractions (1 min) were collected and radioactivity
determined by scintillation counting. Total radioactivity
corresponding to the region of phosphotriester elution and
the marker peaks were calculated.
Cell survival assay
AB1157 (wild type) or the isogenic GWR111 (adaÿ/ogtÿ)
cells containing the plasmids pMAL-2c (control) or
pMAL-2c-ATL or -MGMT were grown in 10 ml of LB sup-
plemented with 50 mg/ml of ampicillin at 37C with shaking
at 220 r.p.m. (orbital shaker; Forma Scientific) to an OD600 of
0.5. Immediately prior to plating, round-bottomed 96-well
plates were prepared by adding 100 ml of LB containing
increasing concentrations of MNNG. The cultures were
diluted 100-fold into fresh LB and 100 ml plated into each
well of the plate. The plates were incubated at 37C for 16 h.
Each well was then resuspended and the OD600 measured
using a Tecan plate reader. Results were expressed as a per-
centage of control (vehicle-treated) growth.
RESULTS
ATL is not an alkyltransferase protein
Using incubation and processing conditions under which
human MGMT rapidly transferred [3H]-methyl groups from
[3H]-methylated substrate DNA to protein, purified ATL
displayed no ability to undertake this reaction (Figure 1A)
even after an incubation period of 6 h (Figure 1B). Conversion
of the ATL putative active site W83 to C83 (or, as a negative
control, A83) did not confer methyl transfer capacity on the
ATL protein under the incubation conditions used. As expec-
ted, conversion of the active site C145 in human MGMT to
W145 removed its methyl transfer capacity (Figure 1A).
The nature of the MGMT assay would not allow us to assess
if [3H]-methyl groups had been released from the O6-meG in
substrate DNA into solution by ATL or if the strong acid
hydrolysis step of the assay may have degraded a putative
methylated ATL protein to acid solubility. To determine
this, we used mild acid hydrolysis and HPLC to determine
the amounts of O6-meG in substrate DNA. Incubation with
ATL for 6 h had no detectable effect on O6-meG levels,
whereas methyl transfer to the human MGMT under protein
limiting conditions substantially reduced the amounts of
O6-meG in the substrate. There were no detectable differences
in the amounts of 7-methylguanine, 3-methyladenine or phos-
photriesters in the [3H]-methylated substrate DNA following
incubation with either MGMT or ATL (Figure 2).
To further explore the resistance of O6-meG to demethyla-
tion by ATL, oligonucleotides containing O6-meG in a
PstI restriction endonuclease site were 50 end-labelled with
[32P], incubated with ATL, or MGMT, de-proteinized and
subjected to PstI digestion and denaturing gel electropho-
resis. While MGMT restored the blocked digest site and
resulted in two fragments following PstI digestion, no such
cleavage was seen following incubation with ATL again
indicating that demethylation had probably not occurred
(Figure 3).
ATL inhibits the action of MGMT on O6-meG in DNA
Although ATL displays no ability to release or transfer methyl
groups from O6-meG in substrate DNA, we found that the
ability of MGMT to transfer methyl groups was extensively
inhibited by the presence of ATL during the incubation. In
initial assays, ATL was pre-incubated with substrate DNA for
10 min and then a protein-limiting amount of MGMT was
added and incubation continued for a further 50 min. Under
these conditions, inhibition of MGMT activity was propor-
tional to the amount of ATL added. The C83 or A83 mutant
proteins were both, and to a similar extent, rather less effective
than wild-type protein (Figure 4A). The MGMT W145 mutant
did not inhibit methyl transfer by wild-type MGMT under the
assay conditions used (data not shown).
The ATL-mediated inhibition of MGMT was reversible.
Using amounts of the wild type, C83 or A83 proteins that
were approximately equally effective in the inhibition of
MGMT seen above (1.4, 5.7 and 5.7 mg, respectively), pro-
gressively more methyl transfer to MGMT occurred with time
up to 6 h (Figure 4B). The wild-type and both mutant
proteins showed almost identical kinetics of loss of inhibition.
Figure 1. Transfer of [3H]methyl groups from [3H]-methylated substrate DNA
to protein. (A) Substrate was incubatedwith the proteins indicated for 60min at
37C. (B) Substrate was incubated with MGMT, ATL wild type, ATL C83 and
ATL A83 for up to 6 h at 37C.
3840 Nucleic Acids Research, 2005, Vol. 33, No. 12
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In agreement with the methyl transfer assays (see above),
HPLC analysis also showed that MGMT could partially
deplete the levels of O6-meG in substrate DNA after 6 h
incubation in the presence of ATL (Figure 2).
ATL binds specifically to O6-meG in DNA
To examine the mechanism by which ATL inhibited the
action of MGMT on O6-meG in substrate DNA, we incubated
32P-labelled synthetic oligonucleotides containing single O6-
meG residues with purified ATL and analysed the products by
non-denaturing gel electrophoresis and phosphorimaging.
ATL was able to bind to O6-meG-containing, but not control
(G replacing O6-meG) oligos in either single- or double-
stranded form (Figure 5). That the shifted band had the
same electrophoretic mobility when either single- or
double-stranded substrate was used may indicate that ATL
had denatured the double-stranded oligonucleotide. Factor
Xa cleaved fusion protein also produced a gel shift, while
purified MBP did not, demonstrating that the shift was a func-
tion of ATL binding (Figure 5).
Similar gel shifts were seen using double-stranded oligo-
nucleotides, in which the base complementary to O6-meG was
T, C, G or A (Figure 6A). However, oligonucleotides contain-
ing O4-methylthymine, 8-oxoguanine, 5-hydroxycytosine or
ethenoadenine (Figure 6B) did not bind to ATL in either
Figure 2.Amounts ofmethylphosphotriesters andmethylated purines inHPLC
fractionated mild acid hydrolysates of [3H]-methylated substrate DNA follow-
ing incubation for 6 h at 37C with MGMT, ATL or a combination of MGMT
and ATL (ATL pre-incubated with substrate for 10 min at 37C). HPLC con-
ditions are described in Materials and Methods. PTE, region of elution profile
containing phosphotriesters and methylated pyrimidines.
Figure 3. Phosphorimage of 50-32P-labelled oligonucleotides after denaturing
PAGE.Lane 1,marker 6mer (GGACTG); lanes 2 and3, single-stranded (ss) and
double-stranded (ds) O6-meG-containing oligonucleotides, respectively; lanes
4 and 5, control (does not contain the O6-meG) and O6-meG double-stranded
oligonucleotides, respectively, digested with PstI; lanes 6 and 7, dsO6-meG
oligonucleotides pre-incubated with MGMT or ATL, respectively, purified
(Materials and Methods) and digested with PstI.
Figure 4. Effect of ATL wild-type, ATL C83 and ATL A83 on the transfer of
radioactivity from [3H]-methylated substrate DNA to MGMT. Substrate was
incubated with the proteins for 10 min before the addition of MGMT and (A)
incubated for a further 50min at 37Cwith incrementally increasing amounts of
protein, or (B) incubatedwithoutATLorwith a fixed amount ofATLprotein for
up to 6 h.
Nucleic Acids Research, 2005, Vol. 33, No. 12 3841
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single- or double-stranded form. This indicates that among the
base modifications examined, ATL binding was specific for
O6-meG.
ATL has no apparent endonuclease or glycosylase
activity
In order to assess if ATL had endonuclease activity, ATL-
treated O6-meG-containing oligonucleotides were heat
denatured and subject to denaturing gel electrophoresis.
There was no evidence of cleavage at or near the location
of the O6-meG residue (Figure 7, lanes 9 and 10). We also
noted in this study that heat denaturation of the ATL-O6-meG-
containing oligonucleotide complex (at 95C for 10 min)
appeared not to completely dissociate the complex, or the
complex was reformed on cooling (Figure 7, lane 9).
The possibility that ATL may be a glycosylase acting on
O6-meG in DNA was assessed by incubation of ATL-treated
O6-meG-containing oligos with formamidopyrimidine glyc-
osylase (FPG), which has AP lyase activity. In contrast to
the FPG-mediated cleavage seen using the 8-oxoguanine-
containing oligonucleotide, the ATL-FPG combination did
not result in cleavage of the O6-meG-containing oligonuc-
leotides (Figure 7, lanes 1–8).
Sensitization of E.coli to MNNG by ATL
Overexpression of ATL in the wild-type E.coli AB1157
increased sensitivity to the toxic effects of MNNG, in contrast
to the protective effect provided by the overexpression of
human MGMT (Figure 8A). In the isogenic adaÿ/ogtÿ strain
(GWR111), which is MNNG-sensitive, there was a greater
protection provided by human MGMT, but there was no effect
of ATL overexpression (Figure 8B).
DISCUSSION
The primary sequence similarities between ATL and proka-
ryotic and eukaryotic alkyltransferase proteins led us to
hypothesize that ATL may have a role in processing the
type of DNA damage that is repaired by MGMT. The presence
of a tryptophan residue in place of cysteine at the region of
ATL that is homologous to the active site of MGMT sugges-
ted that the ATL protein would not be an alkyltransferase but
might be an unusual demethylase, glycosylase or endonuc-
lease. Whether or not conversion of the W83 to C83
would confer alkyltransferase activity was also considered.
Our initial approach was to assess the effect of ATL and the
C83 and A83 mutants on [3H]-methylated substrate DNA.
Under assay conditions in which MGMT was highly effective,
no transfer of radioactivity to protein was evident with any of
these proteins. The absence of transfer activity in the C83
mutant, which has the putative active site sequence identical
to that of MGMT, is intriguing, given that many of the other
residues around the active site of MGMT that are required
for alkyl transfer function (12,13) are also present in ATL.
Presumably, other amino acid residues essential for this func-
tion are missing from ATL.
Although no O6-meG processing was seen (see below),
it was very clear that preincubation of the substrate DNA
Figure 5. Phosphorimage of 50-32P-labelled oligonucleotides after
non-denaturing PAGE. Lanes 1 and 2, ss- and dsO6-meG oligonucleotides,
respectively; lanes 3 and 4, as 1 and 2 but following incubation with ATL;
lane 5, dsO6-meGoligonucleotide incubatedwith factorXa cleavedMBP–ATL
fusion protein; lane 6, as lane 2 but following incubation with MBP alone; lane
7, dscontrol oligonucleotide after incubation with ATL.
Figure 6. Phosphorimages of 50-32P-labelled oligonucleotides after incubation
with ATL and non-denaturing PAGE. (A) Lane 1, dsO6-meG oligonucleotide
(no ATL control); lanes 2–5, dsO6-meG oligonucleotides where the O6-meG
adduct was paired with C, A, T or G (lanes 2–5, respectively). (B) Single (lanes
1–5) and double (lanes 6–11) stranded oligonucleotides containing O6-meG
(lanes 1 and 6), control oligonucleotides (lanes 2 and 7), 8-oxoguanine (lanes 3
and 8), 5-hydroxycytosine (lanes 4 and 9), ethenoadenine (lanes 5 and 10) and
dsO4-methylthymine (lanes 11).
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with ATL could almost completely inhibit the transfer of
methyl groups from O6-meG to human MGMT. This was also
the case but to a lesser extent, with the mutant ATL proteins,
whereas no inhibition was seen using similar quantities of the
W145 mutant of MGMT. For all three ATL proteins, continu-
ing the incubation after the addition of MGMT resulted in
progressively more methyl transfer to MGMT, suggesting
that the binding was competitive with that of MGMT. The
mutations we had introduced did not appear to have a major
impact on such binding. We cannot exclude the possibility
that the reversal of inhibition represents a slow denaturation
of the ATL proteins, although the gel-shift assay results that
involved thermal denaturation suggest that this might not be
the case. However, it seems more likely that the bound ATL
protein is in equilibrium with the free protein and that MGMT
competes with ATL for the O6-meG in substrate DNA. These
data are difficult to interpret since, given that the assay for
ATL activity is indirect, we cannot determine the number of
functionally active ATL molecules, so the stoichiometry of the
inhibition cannot be established. Inhibition of MGMT by
ATL resembles the action of the A145 mutant of MGMT,
which binds toO6-meG and is reported to mask it from nucleo-
tide excision repair (14). Masking and protection of
O4-methylthymine in DNA against nucleotide excision repair
has also been observed with wild-type (15) and mutant (14)
MGMT.
The slow reversal of MGMT inhibition by ATL provides
further evidence that the O6-meG in the substrate DNA was
not affected by ATL. We confirmed this by HPLC analysis
of the substrate following incubation with amounts of ATL
that inhibited MGMT. This showed no change in the amounts
of O6-meG that had been structurally modified by ATL, as had
originally been reported for the action of the ada alkyltrans-
ferase onO6-meG in DNA (16), but that the products co-eluted
with the marker O6-meG seems improbable but was made
even less likely by the use of reverse-phase HPLC. This
also demonstrated no ATL-mediated decrease in the size of
the O6-meG peak (data not shown).
Binding of ATL to O6-meG was further confirmed in
non-denaturing gel-shift assays using either single- or
double-stranded synthetic oligonucleotides containing single
O6-meG residues, paired in the latter case with T, C, G or A.
We also showed that this binding is specific insofar as
oligonucleotides containing 8-oxoguanine, ethenoadenine,
5-hydroxycytosine or O4-methylthymine did not bind to
ATL under the same conditions. The ability of ATL to bind
to O6-meG in the oligonucleotides appears to be preserved
after heat denaturation, suggesting that the protein is thermo-
stable, or rapidly renatures upon cooling.
MGMT did not result in any visible gel shift using O6-meG-
containing oligonucleotides under the conditions we used,
indicating that ATL binding may have been much stronger
than that of MGMT. However, it has been shown that modi-
fication of the active site cysteine residue alters the affinity of
MGMT for DNA (17) and this may be the reason that we did
not see a gel shift with this protein.
In support of the HPLC analyses, restriction endonuclease
digestion of ATL-treated O6-meG-containing oligonuc-
leotides did not restore the PstI site therein and thus gave
no evidence of a demethylase activity; we did not see evidence
of glycosylase or endonuclease activity on the O6-meG-
containing oligonucleotides. It is important to note that in most
of the assays we have used one set of experimental conditions
and we cannot exclude the possibility that different conditions
may have led us to other conclusions. Nevertheless, it seems
Figure 7. Phosphorimage of 50-32P-labelled oligonucleotides after denaturing
PAGE. Lane 1, dsO6-meG oligonucleotide; lanes 2 and 3, marker 5 and 6mer
oligonucleotides; lanes 4 and 5, O6-meG (lane 4) and control (lane 5)
ds-oligonucleotides incubated with FPG; lanes 6 and 7, O6-meG (lane 6)
and control (lane 7) ds-oligonucleotides pre-incubated with ATL, purified
and incubated with FPG; lane 8, ds8-oxoG oligonucleotide incubated with
FPG. Lanes 9 and 10 (no cleavage is seen in the absence of FPG; data not
shown): O6-meG and control ds-oligonucleotide, respectively, incubated with
ATL then heated to 95C for 10 min before electrophoresis.
Figure 8. Effects of ATL and MGMT overexpression, in comparison with
control, on the toxic effects of MNNG inWT (A) and isogenic ada-ogt- double
mutants (B).
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reasonable to conclude that ATL binds specifically to O6-meG
in methylated DNA and one consequence of this is that access
of MGMT to the damage is restricted. The ability of ATL to
bind but not to modify O6-meG in DNA suggests that it may
act as a damage sensing protein that flags such damage for
processing by other repair pathways. However, in most of the
organisms we have examined in silico (the exceptions being
S.pombe and Deinococcus), ATL encoding genes are present
in addition to recognizable alkyltransferase genes. Our in vitro
results indicate that ATL may mask O6-meG from efficient
repair by such alkyltransferases.
This possibility was examined by the overexpression of
ATL in isogenic E.coli strains differing in endogenous alkyl-
transferase activity. Thus, in the wild-type AB1157 strain,
and in support of the in vitro results, ATL increased the
toxic effects of the methylating agent MNNG, presumably
by attenuating the repair of O6-meG by the endogenous alkyl-
transferases. In non-adapted E.coli, this would predominantly
be by OGT and to a lesser extent by ADA (18). Overexpres-
sion of human MGMT in this strain complemented the effects
of the endogenous proteins and reduced the toxicity of MNNG.
In the MNNG-sensitive adaÿ/ogtÿ strain, overexpression of
human MGMT had a very substantial protective effect, but
ATL did not affect the toxicity of MNNG. This suggests that
ATL is not the rate-limiting step in O6-meG processing in the
absence of OGT and ADA, again in support of the in vitro data.
In conclusion, we have shown that the ATL protein from
E.coli has the ability to bind specifically to O6-meG in oligo-
nucleotides and DNA without methyl transfer or removal or
glycosylase or endonuclease activity. The binding strongly,
but reversibly, inhibits the action of MGMT on O6-meG
in substrate DNA. Overexpression of ATL in E.coli increases
the toxicity of MNNG probably via binding to O6-meG
and inhibition of endogenous alkyltransferase. It seems reas-
onable to speculate that the function of ATL is not the inhibi-
tion of alkyltransferase activity. It is more likely that it act as a
damage sensor that flags O6-alkylguanine lesions for pro-
cessing by other pathways. It would thus complement alkyl-
transferase activity in situations where the number or type of
lesions present are not effectively repaired by alkytransferase.
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